e-ISSN: Pending
Negative / Null Result ReportOpen accessMedicine· cited by 56

Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma

Wei‐Cheng Lin; Yi‐Fang Ding; Han‐Lin Hsu; Jer‐Hwa Chang; Kevin Sheng‐Po Yuan; Alexander T.H. Wu; Jyh‐Ming Chow; Chia‐Lun Chang · 2017 · Cancer

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

BACKGROUND: Few large, prospective, randomized studies have investigated the value and optimal application of neoadjuvant chemoradiotherapy followed by surgery (trimodality therapy) or definitive concurrent chemoradiotherapy (CCRT) for patients with thoracic esophageal squamous cell carcinoma (TESCC). METHODS: The authors analyzed data from patients with TESCC in the Taiwan Cancer Registry database. To compare their outcomes, patients with TESCC were enrolled and categorized into the following groups according to treatment modality: group 1, those who underwent surgery alone; group 2, those wh

Abstract by Wei‐Cheng Lin; Yi‐Fang Ding; Han‐Lin Hsu; Jer‐Hwa Chang; Kevin Sheng‐Po Yuan; Alexander T.H. Wu; Jyh‐Ming Chow; Chia‐Lun Chang, Cancer (2017) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1002/cncr.30823